Efficacy and safety of ATX‐101 as a treatment for submental fullness: A retrospective analysis of two aesthetic practices. (25th September 2019)

• Record Type: Journal Article
• Authors: Zarbafian, Misha; Karavan, Mahsa; Greene, Ryan; Fabi, Sabrina Guillen
• Is Part Of: Journal of cosmetic dermatology. Volume 19:Number 6(2020)
• Page Start: 1328
• Page End: 1332
• Publication Date: 2019-09-25
• Subjects: ATX‐101 -- clinical -- injectables -- lipolysis -- submental fullness; Skin -- Diseases -- Treatment -- Periodicals; Lasers in surgery -- Periodicals; Skin -- Pathophysiology -- Periodicals; Surgery, Plastic -- Periodicals; 616.5
• DOI: 10.1111/jocd.13165
• Languages: English
• ISSNs: 1473-2130

Abstract

Abstract: Background: Submental fullness (SMF) is a common cosmetic concern that can have negative impact on one's self‐esteem. ATX‐101 has shown promise as a minimally invasive treatment for SMF correction in clinical trials. Aims: To assess the safety and efficacy of ATX‐101 for SMF correction. Patients/Methods: This was a retrospective review of 90 patients from two aesthetic practices who received ATX‐101 injections for SMF (January 2016‐August 2017). There were no exclusion criteria. Initial SMF severity was assigned using standardized photographs and a validated 5‐point scale. Eighty one patients subsequently answered questionnaires regarding improvement, satisfaction, and adverse effects. Degree of SMF correction was also evaluated by the investigator and a blinded reviewer. Results: Eighty one patients (mean initial submental fullness severity 1.6) received a mean of 1.84 ATX‐101 treatment sessions using a median of 2.0 vials per treatment (mean 3.02, range 1‐9). Mean Physician Global Aesthetic Improvement Scale scores were 2.73 and 2.25, after the first and second treatments, respectively ( P = .04). Mean Subject Goal Aesthetic Improvement Scale scores were 2.7 and 2.25 after the first and second treatments, respectively ( P = .01). Sixty‐seven percentage of patients were "somewhat" or "very" satisfied. Adverse events were transient and limited to the treatment area. Conclusion: Patients achieved progressive improvement in SMF after the 1st and 2nd treatments, as judged by patients themselves, investigators, and blinded evaluators. These results of SMF correction suggest that significant benefit can be obtained with proper dosing at the initial visit. These data support the efficacy and safety profile of ATX‐101 use for SMF correction.